Ajanta Pharma Limited (NSE: AJANTPHARM) and Emcure Pharmaceuticals Ltd (NSE: EMCURE) are both listed in the Pharmaceuticals industry. Ajanta Pharma has a market capitalisation of ₹42,432 Cr and Emcure Pharmaceuticals ₹35,726 Cr, as of 9 Nov 2026. Their P/E ratios are 40.2 and 38.6 respectively. Return on equity is 25.39% for Ajanta Pharma and 19.57% for Emcure Pharmaceuticals. Over one year, Ajanta Pharma's share price is up 35.7% and Emcure Pharmaceuticals's is up 67.0%.
| Metric | Ajanta Pharma | Emcure Pharmaceuticals |
|---|---|---|
| NSE Symbol | AJANTPHARM | EMCURE |
| BSE Code | 532331 | 544210 |
| Share Price | ₹3,345.50 | ₹2,215.00 |
| Market Cap | ₹42,432 Cr | ₹35,726 Cr |
| P/E Ratio | 40.2 | 38.6 |
| Return on Equity | 25.39% | 19.57% |
| Return on Assets | 14.85% | 9.62% |
| Dividend Yield | 1.88% | 0.19% |
| Beta (1Y) | 0.12 | -0.01 |
| 1-Year Price Change | +35.7% | +67.0% |
| 3-Month Price Change | -4.6% | +11.0% |
| 52-Week Range | ₹2,445.80 – ₹3,796.00 | ₹1,312.30 – ₹2,280.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹1,794 Cr | ₹2,820 Cr |
| Quarterly Net Profit | ₹388 Cr | ₹325 Cr |
| Net Margin | 21.6% | 11.5% |
| EPS (Basic, Quarter) | ₹31.07 | ₹17.16 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Pune, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 19…
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglut…
Ajanta Pharma has a market capitalisation of ₹42,432 Cr, against ₹35,726 Cr for Emcure Pharmaceuticals as of 9 Nov 2026, about 1.2 times the size by market cap.
Ajanta Pharma has a P/E of 40.2 and Emcure Pharmaceuticals a P/E of 38.6 as of 9 Nov 2026.
Ajanta Pharma has a return on equity of 25.39% and Emcure Pharmaceuticals 19.57%.
Ajanta Pharma's share price is up 35.7% over one year and Emcure Pharmaceuticals's is up 67.0%.
Ajanta Pharma reported revenue of ₹1,794 Cr and net profit of ₹388 Cr for Q2 FY27. Emcure Pharmaceuticals reported revenue of ₹2,820 Cr and net profit of ₹325 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.